Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying Disease
Open Access
- 13 July 2021
- journal article
- research article
- Published by SAGE Publications in International Journal of Toxicology
- Vol. 40 (4) , 322-336
Abstract
Myostatin is a negative regulator of skeletal muscle and has become a therapeutic target for muscle atrophying disorders. Although previous inhibitors of myostatin offered promising preclinical data, these therapies demonstrated a lack of specificity toward myostatin signaling and have shown limited success in the clinic. Apitegromab is a fully human, monoclonal antibody that binds to human promyostatin and latent myostatin with a high degree of specificity, without binding mature myostatin and other closely related growth factors. To support the clinical development of apitegromab, we present data from a comprehensive preclinical assessment of its pharmacology, pharmacokinetics, and safety across multiple species. In vitro studies confirmed the ability of apitegromab to inhibit the activation of promyostatin. Toxicology studies in monkeys for 4 weeks and in adult rats for up to 26 weeks showed that weekly intravenous administration of apitegromab achieved sustained serum exposure and target engagement and was well-tolerated, with no treatment-related adverse findings at the highest doses tested of up to 100 mg/kg and 300 mg/kg in monkeys and rats, respectively. Additionally, results from an 8-week juvenile rat study showed no adverse effects on any endpoint, including neurodevelopmental, motor, and reproductive outcomes at 300 mg/kg administered weekly IV. In summary, the nonclinical pharmacology, pharmacokinetic, and toxicology data demonstrate that apitegromab is a selective inhibitor of proforms of myostatin that does not exhibit toxicities observed with other myostatin pathway inhibitors. These data support the conduct of ongoing clinical studies of apitegromab in adult and pediatric patients with spinal muscular atrophy (SMA).Keywords
This publication has 42 references indexed in Scilit:
- Role of satellite cells versus myofibers in muscle hypertrophy induced by inhibition of the myostatin/activin signaling pathwayProceedings of the National Academy of Sciences, 2012
- Regulation of Muscle Mass by Follistatin and ActivinsMolecular Endocrinology, 2010
- Activin in the Brain Modulates Anxiety-Related Behavior and Adult NeurogenesisPLOS ONE, 2008
- Myostatin does not regulate cardiac hypertrophy or fibrosisNeuromuscular Disorders, 2007
- Myostatin expression in ventricular myocardium in a rat model of volume‐overload heart failureEuropean Journal of Clinical Investigation, 2006
- Myostatin Mutation Associated with Gross Muscle Hypertrophy in a ChildNew England Journal of Medicine, 2004
- Preclinical safety evaluation of biotechnology-derived pharmaceuticalsNature Reviews Drug Discovery, 2002
- Myostatin, a transforming growth factor-? superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarctJournal of Cellular Physiology, 1999
- Regulation of skeletal muscle mass in mice by a new TGF-p superfamily memberNature, 1997
- Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use (1997)Journal of Immunotherapy, 1997